Heavy! 2019 China's pharmaceutical industry top 100 series list released!

Pharmaceutical Network July 23rd , the 2019 China Pharmaceutical Industry Top 100 Series list was released, various enterprises in 2019 to strive for the community to contribute their own energy.
they have never slacked off, only to become the leader and leader of China's pharmaceutical industry. After the
outbreak, in many industrial policies to deepen the current, the pharmaceutical and health industry needs to return, return to the essence of the industry, return to industrial value, return to the health goal, grasp the pulse of the times of those tides, will really stand in the industry's first echelon, not afraid of wind and rain, achievement benchmark.
let us focus on the top 100 enterprises, the strong will continue to cheer in their time! In the 2019 Top100 ranking of Chinese chemical pharmaceutical enterprises, Hengrui Pharmaceuticals, China Biopharmaceuticals and Shanghai Pharma ranked in the top three; PharmaMing Bio, Tag Pharmaceuticalrank i.A. Ranked in the top three in the 2019 Top20 ranking of China's medical devices (including IVD) enterprises, Meirui Medical, Viago shares, Lepu Medical ranked in the top three, and in the 2019 China Biopharmaceutical (including blood products, vaccines, insulin, etc.) enterpriseTOP20 ranking, Baiji Shenzhou, Changchun, Zhifei Bio ranked in the top three.
congratulations on the 2019 China Pharmaceutical Industry Top 100 Series list of 260 enterprises, they are the benchmark and role model of China's pharmaceutical industry.
they withstood the test, has been recognized by the community and the market, and finally won their own honor! The final list of the 2019 China Pharmaceutical Industry Top 100 Series will be awarded at the "2020 National Pharmacy Week and China Pharmaceutical Industry Top 100 Annual Meeting and China Pharmaceutical Internet Economy Annual Meeting" in Yunnan from August 25-28, 2020.
this selection focuses on the innovation driving force and professional promotion of pharmaceutical industry enterprises, the innovation driving force is mainly judged from the comprehensive index of enterprise research and development investment R and D, the professional promotion is focused on the clinical practitioners and patients' final selection of the demand for the final choice of the terminal quantitative data to rigidly define, and finally combined with the exclusive three terminal son of the net terminal terminal data quantitative analysis.
"2019 China's top 100 pharmaceutical industry series list" the specific selection rules are as follows: 1." 2019 China's top 100 pharmaceutical industry series "selection time span from January 1 to December 31, 2019; The 2019 Top 100 List of China's Pharmaceutical Industry is divided into top 100 rankings of Chinese pharmaceutical companies, TOP100 rankings for Chinese chinese medicine enterprises, TOP20 rankings for Chinese CRO (including CDMO) enterprises, TOP20 rankings for Chinese medical devices (including IVD), top20 rankings for Chinese biomedicine (including blood products, vaccines, insulin, etc.)
According to the unified opinion of the Expert Committee of the Top 100 Of China's Pharmaceutical Industry, led by the Minne Research Institute, the core competitiveness elements among the major sub-sectors of China's pharmaceutical industry are not the same, and it is not possible to conduct far-fetched horizontal comparisons.
, the refore, the Minne Research Institute respects the views of the Expert Committee, this 2019 China Pharmaceutical Industry Top 100 series list does not set a total list; Biopharmaceuticals, etc. are included in the Top100 ranking data of Chinese chemical pharmaceutical enterprises in a unified ranking, the definition method sedative methods and statistical scope of the ranking data of other sub-list enterprises are the same; 4. List selection method: "2019 China's pharmaceutical industry top 100 series list" candidate scoring the total score of two parts, one is the enterprise's innovation driving force, that is, the 2019 research and development investment R and D comprehensive index score, accounting for 40%; That is, in 2019 clinicians and patients' final choice of the final choice of the final quantitative data to rigidly define, that is, combined with the minet network exclusive three terminals six market terminal data for quantitative analysis of the score, accounting for 60% of the weight;
if the selection enterprise contains pharmaceutical commercial or other non-pharmaceutical components, it will be excluded and then counted; the object of participation in the selection does not include pharmaceutical machinery and veterinary drug manufacturing enterprises; 6. The scope of the group company statistics is a wholly-owned subsidiary of the group company, the direct or indirect equity ratio of more than 50% of the holding company, the participating company is not within the scope of the group company statistics.
the selection of the "2019 China Pharmaceutical Industry Top 100 Series List" as a public welfare activities, we will continue to uphold the "fair, just and open" principle, and strictly participate in the enterprise to fill in the business indicators data to be kept confidential, the data involved in the selection of this list only for use.
.